Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 15/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 8/20 | 1.00 |
| ▸ | ADORA2A | P29274 | 6/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1569329 | 0.94 | ADORA2B (0.89) | ADORA2BADORA1ADORA2A | |
| SCHEMBL1780628 | 0.92 | ADORA2B (1.00) | ADORA2BADORA1ADORA2A | |
| SCHEMBL1779738 | 0.90 | ADORA2B (1.00) | ADORA2BADORA1ADORA2A | |
| SCHEMBL14267751 | 0.90 | ADORA2B (1.00) | ADORA2BADORA1ADORA2A | |
| SCHEMBL1778231 | 0.89 | ADORA2B (1.00) | ADORA2BADORA1ADORA2A | |
| SCHEMBL4759214 | 0.84 | ADORA2B (0.75) | ADORA2BADORA1ADORA2A | |
| SCHEMBL1782025 | 0.80 | ADORA2B (1.00) | ADORA2BADORA1ADORA2A | |
| SCHEMBL5336024 | 0.80 | ADORA2B (0.83) | ADORA2BADORA1ADORA2A | |
| SCHEMBL14517865 | 0.80 | ADORA2B (0.82) | ADORA2BADORA1ADORA2A | |
| SCHEMBL5334257 | 0.79 | ADORA2B (0.82) | ADORA2BADORA1ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 274 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4567112-A1 | RNA INHIBITOR FOR INHIBITING APOC3 GENE EXPRESSION AND USE THEREOF | Kylonova (Xiamen) Biopharma Co., Ltd. (CN) | 2025-06-11 | — | — | EP | claimed |
| CN-118215665-A | Beta-lactamase inhibitor intermediate and preparation method thereof | 苏州信诺维医药科技股份有限公司 | 2024-06-18 | — | — | CN | claimed |
| US-20230340237-A1 | LIQUID HYDROGENATED NITRILE-BUTADIENE RUBBER, PREPARATION METHOD THEREOF AND USE THEREOF | ZANNAN SCITECH CO., LTD. (CN) | 2023-10-26 | — | — | US | claimed |
| CN-114262394-B | Liquid hydrogenated nitrile rubber and preparation method and application thereof | 浙江赞昇新材料有限公司 | 2023-08-18 | — | — | CN | claimed |
| CN-114262394-A | Liquid hydrogenated nitrile rubber and preparation method and application thereof | 浙江赞昇新材料有限公司 | 2022-04-01 | — | — | CN | claimed |
| US-20110118276-A1 | METHODS OF TREATING ATHEROSCLEROSIS | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT INC | 2011-05-19 | — | — | US | claimed |
| US-7205403-B2 | 8-Heteroaryl xanthine adenosine A2B receptor antagonists | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) | 2007-04-17 | — | — | US | claimed |
| US-20060142309-A1 | 8-Heteroaryl xanthine adenosine A2B receptor antagonists | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2006-06-29 | — | — | US | claimed |
| US-20030207879-A1 | 8-Heteroaryl xanthine adenosine A2B receptor antagonists | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2003-11-06 | — | — | US | claimed |
| CN-122092907-A | Photovoltaic optimizer communication method and system based on PLC | — | 2026-05-26 | — | — | CN | disclosed |
| CN-121463259-B | Communication method, device and system | Honor Terminal Co.,Ltd. (CN) | 2026-05-26 | — | — | CN | disclosed |
| CN-118003730-B | Weather-resistant polyolefin film and solar cell backboard prepared from same | LUCKY FILM CO.,LTD. (CN) | 2026-05-26 | — | — | CN | disclosed |
| WO-2026107232-A1 | METHODS FOR PREPARING MYCELIUM SHEET OR PANEL MATERIAL FOR FURTHER PROCESSING AND/OR FINISHING | ECOVATIVE LLC (US) | 2026-05-21 | — | — | WO | disclosed |
| CN-122069488-A | Intelligent iron shoe control method, intelligent iron shoe control equipment, intelligent iron shoe control medium, intelligent iron shoe product and intelligent iron shoe | 株洲太昌电子信息技术股份有限公司 | 2026-05-19 | — | — | CN | disclosed |
| US-20110118276-A1 | METHODS OF TREATING ATHEROSCLEROSIS | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT INC | 2011-05-19 | — | — | US | disclosed |
| US-7335655-B2 | 8-heteroaryl xanthine adenosine A2B receptor antagonists | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) | 2008-02-26 | — | — | US | disclosed |
| US-7335655-B2 | 8-heteroaryl xanthine adenosine A2B receptor antagonists | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) | 2008-02-26 | — | — | US | disclosed |
| US-7335655-B2 | 8-heteroaryl xanthine adenosine A2B receptor antagonists | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) | 2008-02-26 | — | — | US | disclosed |
| US-7205403-B2 | 8-Heteroaryl xanthine adenosine A2B receptor antagonists | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. (US) | 2007-04-17 | — | — | US | disclosed |
| US-20060142309-A1 | 8-Heteroaryl xanthine adenosine A2B receptor antagonists | KING PHARMACEUTICALS RESEARCH AND DEVELOPMENT, INC. | 2006-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230340237-A1 | LIQUID HYDROGENATED NITRILE-BUTADIENE RUBBER, PREPARATION METHOD THEREOF AND USE THEREOF | NOS1, NOS2, NOTUM | ADORA2B 3904/4885ADORA1 3430/4885ADORA2A 4621/4885 |
| US-20110118276-A1 | METHODS OF TREATING ATHEROSCLEROSIS | ADORA2B, ADORA2A, ADORA3 | ADORA2B 1/4885ADORA1 4/4885ADORA2A 2/4885 |
| US-20030207879-A1 | 8-Heteroaryl xanthine adenosine A2B receptor antagonists | ADORA2B, ADORA2A, ADORA1 | ADORA2B 1/4885ADORA1 3/4885ADORA2A 2/4885 |
| US-20060142309-A1 | 8-Heteroaryl xanthine adenosine A2B receptor antagonists | ADORA2B, ADORA2A, ADORA1 | ADORA2B 1/4885ADORA1 3/4885ADORA2A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.